QQ客服 官方微博 反馈留言

浏览/检索结果: 共6条，第1-6条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40 作者:  Li, Ning;  Zhang, Youzhong;  Wang, Jing;  Zhu, Jianqing;  Wang, Li 收藏  |  浏览/下载：27/0  |  提交时间：2022/12/22 Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors 期刊论文 CHINESE JOURNAL OF CANCER RESEARCH, 2020, 卷号: 32, 期号: 3, 页码: 370-+ 作者:  Li, Huiping;  Liu, Rongrui;  Shao, Bin;  Ran, Ran;  Song, Guohong 收藏  |  浏览/下载：22/0  |  提交时间：2020/12/24 Phase I  PARP inhibitor (fluzoparib)  solid tumor  pharmacokinetics  safety  antitumor activity   Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials 期刊论文 CANCER SCIENCE, 2019, 卷号: 110, 期号: 3, 页码: 1064-1075 作者:  Wang, Lei;  Yang, Changyong;  Xie, Chengying;  Jiang, Jiahua;  Gao, Mingzhao 收藏  |  浏览/下载：22/0  |  提交时间：2020/07/01 antitumor activity  fluzoparib  pharmacokinetics  poly(ADP-ribose) polymerase  toxicity   Pharmacologic characterization of fluzoparib, a novel poly polymerase inhibitor undergoing clinical trials 期刊论文 Cancer Science, 2019, 卷号: Vol.110 No.3, 页码: 1064-1075 作者:  Lei Wang;  Changyong Yang;  Chengying Xie;  Jiahua Jiang;  Mingzhao Gao 收藏  |  浏览/下载：12/0  |  提交时间：2019/12/13 antitumor activity  fluzoparib  pharmacokinetics  poly(ADP‐ribose) polymerase  toxicity   Pharmacologic Characterization of Fluzoparib, a Novel Poly polymerase Inhibitor Undergoing Clinical Trials. 期刊论文 Cancer science, 2019 作者:  Lei Wang;  Changyong Yang;  Chengying Xie;  Jiahua Jiang;  Mingzhao Gao 收藏  |  浏览/下载：14/0  |  提交时间：2019/12/13 PARP  Antitumor  activity  Fluzoparib  Pharmacokinetics  Toxicity   Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer 会议论文 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SEP 27-OCT 01, 2019 作者:  Li, N.;  Wu, L.;  Zhang, Y.;  Liu, J.;  Zhou, Q. 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/31